Associate Professor of Medicine, Director of the Lung Cancer Medical Oncology Program at CCF
Oncology
Dr. Nathan A. Pennell, MD
|
|
Give Review
Nathan Pennell is an expert in the field of Oncology. He researched medicine at University of Florida College of Medicine. University of Florida College of Medicine is ranked 43 in research and 78 in primary care medicine He received awards:"Associate Editor, ASCO Educational Book", "Consultant Editor", "Best Doctors in America", "Best Doctors", "CMS Meaningful Use Stage 1 Certification", "Teacher of the Year", "Foundation Merit Award" and "President, Florida Beta Chapter". Nathan Pennell is a published doctor and has 35 publications published. The lastest was: 'Fast-Growing Plasmacytoma.' He is registered with Medicare.
Publications
- Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
- EGFR molecular testing in African-American non-small cell lung Cancer patients - a review of discrepant data.
- ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung Cancer patients.
- Treating acquired resistance to EGFR-tyrosine kinase inhibitors:still a work in progress.
- Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung Cancer.
- RET-Rearranged Lung AdenoCarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib.
- Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung Cancer.
- EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung Cancer (NSCLC).
- Comprehensive molecular profiling of lung adenoCarcinoma.
- Treating ALK-positive lung Cancer in the weeks after the FDA approval of crizotinib.
- New guideline sets the ground rules for routine molecular testing in non-small cell lung Cancer.
- High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung Cancer.
- ALK Status Testing in Non-Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material.
- ALK Status Testing in Non-Small Cell Lung Carcinoma: Correlation Between Ultrasensitive IHC and FISH.
- Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?
- Treating Anaplastic Lymphoma Kinase-Positive Lung Cancer in the Weeks After the US Food and Drug Administration Approval of Crizotinib.
- Two generations of light/never-smokers with advanced adenoCarcinoma of the lung with durable responses to erlotinib.
- Selection of chemotherapy for patients with advanced non-small cell lung Cancer.
- XL647-A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatm...
- Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non-Small-cell Lung Cancer.
- Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung Cancer.
- Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung Cancer.
- Time to move beyond clinical and pathologic classification of BAC.
- Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung Cancer after treatment with EGFR inhibitors.
- Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-sma...
- Investigational agents in the management of non-small cell lung Cancer.
- Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
- Gene expression-based survival prediction in lung adenoCarcinoma: a multi-site, blinded validation study.
- A phase II study of gefitinib in patients with advanced thyroid Cancer.
- Patients as real time teachers.
- Interns' work hours.
- Prospective Clinical Study of Precision Oncology in Solid Tumors.
- Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung Cancer.
- Fast-Growing Plasmacytoma.
Schools
University Of Florida College Of Medicine
Brigham and Womens Hospital
DanaFarber Cancer Institute
University of North Carolina At Chapel Hill
University Of Florida
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- CareSource
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Medicare Advantage PFFS
- HealthSmart
- Choice Care PPO
- Kaiser Permanente
- Medicaid
- Medical Mutual of Ohio POS
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Principal Life
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- WellCare
- Wells Fargo Insurance
Awards
- Associate Editor, ASCO Educational Book
- Consultant Editor
- Best Doctors in America
- Best Doctors
- CMS Meaningful Use Stage 1 Certification
- Teacher of the Year
- Foundation Merit Award
- President, Florida Beta Chapter
Education
-
Brigham and Women's Hospital -
University of Florida College of Medicine
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1508836438 | |
| NPPES Provider LastName | PENNELL | |
| NPPES Provider FirstName | NATHAN | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 433.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 29.0 | |
| Percent Opioid Claims | 6.7 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508836438 |
| Last Name Of The Provider | PENNELL |
| First Name Of The Provider | NATHAN |
| View All |
Similar Doctors
|
|
Dr. Bassam N. Estfan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Peereboom, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Susan B. LeGrand, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Ernest C. Borden, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Manmeet S. Ahluwalia, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Pauline Funchain, MD |
|
|
Dr. Michael C. Nemunaitis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Greg V. Manson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dale R. Shepard, MD
This Doctor is OpenDoctor Recommended.
|